|19th October 2020||Gene Liau||7,225||Open or private sale||$38.42||$277,585.95|
|19th October 2020||Gene Liau||24,775||Open or private sale||$37.64||$932,578.07|
|19th October 2020||Gene Liau||1,503||Exercise of derivative||$2.19||$3,291.57|
|19th October 2020||Gene Liau||30,497||Exercise of derivative||$0.60||$18,298.20|
|16th October 2020||Gene Liau||5,851||Open or private sale||$40.00||$234,041.76|
|16th October 2020||Gene Liau||5,851||Exercise of derivative||$0.60||$3,510.60|
|14th October 2020||Group, Llc Redmile||195,158||Open or private purchase||$19.20||$3,747,580.04|
|14th October 2020||Group, Llc Redmile||158,100||Open or private purchase||$18.01||$2,847,665.58|
|14th October 2020||Group, Llc Redmile||2,941,176||Open or private purchase||$17.00||$49,999,992.00|
|14th October 2020||Group, Llc Redmile||2,178,738||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.